HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: thx.2005.056887v1 61/10/903    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, J-Y Articles by Luh, K-T Search for Related Content PubMed PubMed Citation Articles by Wang, J-Y Articles by Luh, K-T Topic Collections Relevant Article

Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas

¹ Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
² Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan

Correspondence to:
Correspondence to:
Dr L-N Lee
Department of Laboratory Medicine, National Taiwan University Hospital, No 7, Chun Shan South Road, Taipei, 100, Taiwan; linalee{at}ccms.ntu.edu.tw

Background: A study was conducted to evaluate the effect of the empirical use of fluoroquinolones on the timing of antituberculous treatment and the outcome of patients with tuberculosis in an endemic area.

Methods: All patients with culture confirmed tuberculosis aged 14 years diagnosed between July 2002 and December 2003 were included and their medical records were reviewed.

Results: Seventy nine (14.4%) of the 548 tuberculosis patients identified received a fluoroquinolone (FQ group), 218 received a non-fluoroquinolone antibiotic (AB group), and 251 received no antibiotics before antituberculous treatment. Fifty two (65.8%) experienced clinical improvement after fluoroquinolone use. In the FQ group the median interval from the initial visit to starting antituberculous treatment was longer than in the AB group and in those who received no antibiotics (41 v 16 v 7 days), and the prognosis was worse (hazard ratio 6.88 (95% CI 1.84 to 25.72)). More patients in the FQ and AB groups were aged >65 years (53.2% and 61.0% v 31.5%), had underlying disease (53.2% and 46.8% v 34.3%), and were hypoalbuminaemic (67.2% and 64.9% v 35.1%). Of the nine mycobacterial isolates obtained after fluoroquinolone use from nine patients whose initial isolates were susceptible to ofloxacin, one (11.1%) was resistant to ofloxacin (after fluoroquinolone use for 7 days). Independent factors for a poor prognosis included empirical fluoroquinolone use, age >65, underlying disease, hypoalbuminaemia, and lack of early antituberculous treatment.

Conclusions: 14.4% of our patients with tuberculosis received a fluoroquinolone before the diagnosis. With a 34 day delay in antituberculous treatment and more frequent coexistence of underlying disease and hypoalbuminaemia, empirical fluoroquinolone treatment was associated with a poor outcome. Mycobacterium tuberculosis isolates could obtain ofloxacin resistance within 1 week.

Abbreviations: AFS, acid-fast smear; FQ, fluoroquinolone; TB, tuberculosis

Keywords: fluoroquinolone; antibiotics; tuberculosis; treatment; prognosis

Relevant Article

Airwaves

Wisia Wedzicha
Thorax 2006 61: 831. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				J.-Y. Wang, L.-N. Lee, H.-C. Lai, S.-K. Wang, I-S. Jan, C.-J. Yu, P.-R. Hsueh, and P.-C. Yang Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure J. Antimicrob. Chemother., May 1, 2007; 59(5): 860 - 865. [Abstract] [Full Text] [PDF]